Novartis AG (ADR) (NVS) Releases Earnings Results, Beats Expectations By $0.05 EPS

Novartis AG (ADR) (NVS) reported quarterly earnings results on Thursday, Apr-21-2016. The company said it had a profit of $1.17 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.05. Analysts had a consensus of $1.12. The company posted revenue of $11600.00 million in the period, compared to analysts expectations of $11783.31 million. The company’s revenue was down -2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.33 EPS.

Many Wall Street Analysts have commented on Novartis AG (ADR). Novartis AG (ADR) was Downgraded by Morgan Stanley to ” Underweight” on Apr 12, 2016. Novartis AG (ADR) was Downgraded by Leerink Partners to ” Mkt Perform” on Mar 23, 2016.

Novartis AG (ADR) opened for trading at $75.83 and hit $76.73 on the upside on Monday, eventually ending the session at $76.3, with a gain of 0.86% or 0.65 points. The heightened volatility saw the trading volume jump to 16,79,724 shares. Company has a market cap of $181,128 M.

Novartis AG is a holding company that through its subsidiaries is engaged in development manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines eye care generic pharmaceuticals preventive vaccines and over-the-counter (OTC) products. The Company’s segments include Pharmaceuticals which include patent-protected prescription medicines; Alcon which include surgical ophthalmic pharmaceutical and vision care products; Sandoz which include generic pharmaceuticals and Consumer Health which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia Exjade Galvus Exforge and Voltaren among others. Its Sandoz products include Valsartan (Diovan) Cyclophosphamide injection and AirFluSal Forspiro among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Novartis AG (ADR)

Leave a Reply

Novartis AG (ADR) - Is it time to Sell?

Top Brokerage Firms are advising their investors on Novartis AG (ADR). Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.